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Abstract
Acute heart failure (AHF) is one the most common causes of morbidity and mortality. The prognosis of patients admitted with
AHF remains dismal, with over 20% experiencing recurrent HF admission and over 20% dying during the first year after initial
admission.
The purpose of this study was to provide contemporary perspective for hospital management of AHF within the context
of the most recent data and to provide guidance, based on expert opinions, to practicing physicians and other healthcare
professionals.
Material and methods: In this paper we reviewed of current updated European Cardiology Society (ESC) HF guideline
(2016) and modern trials for AHF from Medscape database.
Results: Diuretics are the main medications in the treatment of patients with AHF and signs of fluid overload and congestion.
Intravenous vasodilators are the second most used agent in AHF. Their use was shown to be associated with lower mortality,
and a delay in administration was associated with a higher mortality.Use of an inotropic medications (such as dopamine,
dobutamine, milrinone, levosimendan, epinephrine, norepenephrine) should be reserved for patients with a severe reduction
in cardiac output resulting in compromised vital organ perfusion, which occurs most often in hypotensive AHF.
Conclusion: Acute heart failure is a life-threatening medical condition, which needs emergency management for death
prevention.
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Problem statement and analysis of the
recent research
It’s known, that heart failure (HF) is a serious condition in
which the heart is unable to pump enough blood to meet the
needs of the body. Across the world, 17-45% of patients
admitted to hospital with HF die within 1 year of admission
and the majority die within 5 years of admission [1].
The prevalence of HF is approximately 1–2% of the adult
population in developed countries, rising to≥10% among old
people [2]. The lifetime risk of HF at age 55 years is 33% for
men and 28% for women [3].
Acute heart failure (AHF) is one of the most common
causes of morbidity and mortality. AHF occurs as the rapid
development or progression of symptoms and/or signs of
heart failure requiring urgent medical evaluation and treat-
ment. AHF may be present as a first occurrence (de novo) or,
more frequently, as a consequence of acute decompensation
of chronic HF, and may be caused by primary cardiac dys-
function or more frequently precipitated by extrinsic factors
in patients with chronic heart failure [4].
The prognosis of patients admitted with AHF remains
dismal, with over than 20% experiencing recurrent HF on
admission and over than 20% dying during the first year after
initial admission [5]. Moreover, patients with AHF recently
hospitalized are at high risk for future cardiovascular events
and death [6].
In contrast to the state of chronic HF treatment, advances
in the management of AHF have been limited. Therapies for
this condition have generally changed a little over the past
decades, despite ongoing research [7]. Options are limited to
drugs that relieve breathlessness and reduce fluid by increasing
urine production or dilating blood vessels. Drugs that act
directly on the heart muscle to increase the contraction power
can have adverse effects. But none of these medications
does anything to address the underlying cause of HF, leaving
patients at a high risk of death after hospital discharge [1].
The objective of the current work is to provide contem-
porary perspective for hospital management of AHF within
the context of the most recent data and to provide guidance,
based on expert opinions, to practicing physicians and other
healthcare professionals.
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1. Materials and methods
In this paper we reviewed the current updated European Car-
diology Society (ESC) HF guideline (2016) and modern trials
for AHF from Medscape database.
2. Results and Discussion
AHF is the term used to describe the rapid onset or acute wors-
ening of symptoms and signs of HF, associated with elevated
plasma levels of natriuretic peptides. It is a life-threatening
condition that requires immediate medical attention and usu-
ally leads to urgent hospital admission [9].
A large number of classifications of AHF based on differ-
ent criteria have been offered. The following clinical classifi-
cation may be helpful to guide therapy in the initial phase and
carries prognostic information. It is based on bedside phys-
ical examination in order to detect the presence of clinical
symptoms/signs of congestion (‘wet’ vs. ‘dry’, if present vs.
absent) and/or peripheral hypoperfusion (‘cold’ vs. ‘warm’
if present vs. absent) [10]. The combination of these op-
tions identifies four groups: warm and wet (well perfused and
congested) — most commonly present; cold and wet (hypop-
erfused and congested); cold and dry (hypoperfused without
congestion); and warm and dry (compensated, well-perfused
without congestion) [10].
Patients with AHF complicating AMI can be classified
according to Killip and Kimball into class I, no clinical signs
of HF; class II, HF with rales and S3 gallop; class III, with
frank acute pulmonary oedema; class IV, cardiogenic shock,
hypotension (SBP<90 mm/Hg) and evidence of peripheral
vasoconstriction such as oliguria, cyanosis and diaphoresis
[11].
AHF is a life-threatening medical condition, thus rapid
transfer to the nearest hospital should be pursued, prefer-
ably to a site with a cardiology department and/or a coronary
care/intensive care unit [8]. It’s important to make an early
diagnosis of main reason of AHF. In case of acute coronary
syndrome, or rapid and excessive increase in arterial blood
pressure, or severe rhythm disturbances, or acute pulmonary
embolism, etc. patients should be treated due to current guide-
lines.
All patients with AHF should be monitored for transcuta-
neous arterial oxygen saturation (SpO2). In case of SpO2<90%
oxygen therapy is recommended [8].
A management algorithm for patients with AHF is based
on the clinical profile during an early phase (fig. 1). Diuretics
are the main medications in the treatment of patients with
AHF and signs of fluid overload and congestion. Initially,
20–40 mg of intravenous furosemide can be considered in
all AHF patients. To enhance diuresis or overcome diuretic
resistance, options include dual nephron blockade by loop di-
uretics (i.e. furosemide or torasemide) with thiazide diuretics
or natriuretic doses of MRAs [12].
Intravenous vasodilators are the second most used agent
in AHF. Their use was associated with lower mortality, and a
Figure 1. ESC (2016) Algorithm for acute heart treatment
[8]
delay in administration was associated with a higher mortality
[13]. Dose should be carefully controlled to avoid excessive
decrease in blood pressure, which is related to poor outcome.
Vasodilators should be used with caution in patients with
significant mitral or aortic stenosis [8]. Vasodilators should
be avoided in patients with SBP<90 mm/Hg (or with symp-
tomatic hypotension).
Use of inotropic medications (such as dopamine, dobu-
tamine, milrinone, levosimendan, epinephrine, norepenephrine)
should be reserved for patients with a severe reduction in car-
diac output resulting in compromised vital organ perfusion,
which occurs most often in hypotensive AHF. Inotropic agents
are not recommended in cases of hypotensive AHF, where
the underlying cause is hypovolaemia, or other potentially
correctable factors before elimination of these causes [8]. In-
otropes, especially those with adrenergic mechanisms, can
cause sinus tachycardia and may induce myocardial ischaemia
and arrhythmias, thus ECG monitoring is required. Levosi-
mendan is preferable over dobutamine to reverse the effect of
beta-blockade if beta-blockade is thought to be contributing to
hypoperfusion [14], but due to its vasodilatatory effect should
be avoided in case of hypotension (SBP<85 mm/Hg) [15].
Routine use of opioids in AFH patients is not recom-
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mended and decision for its use should be individualized. In
the Acute Decompensated Heart Failure National Registry
(ADHFNR), morphine use was associated with higher rates
of mechanical ventilation, intensive care unit admission and
death [16].
In patients with HF and atrial fibrillation, intravenous
administration of a cardiac glycoside should be considered
for rapid control of the ventricular rate, as recommended by
guidelines [9].
The conventional indications for an intra-aortic balloon
pump are to support the circulation before surgical correction
of specific acute mechanical problems, during severe acute
myocarditis and in selected patients with acute myocardial
ischaemia or infarction before, during and after percutaneous
or surgical revascularization. Ventricular assist devices and
other forms of mechanical circulatory support may be used as
a ‘bridge to decision’ or longer term in selected patients [8].
Mortality and readmission rates after discharge from an
admission with AHF are high [17]. In accordance of recent
French prospective cohort study of patients older than 75 years
who were admitted with AHF, the independent predictors of
2-year mortality were male sex (hazard ratio [HR], 1.36; 95%
CI, 1.00–1.82), age>85 years (HR, 1.57; 95% CI, 1.19–2.07),
higher number of impaired activities of daily living (HR, 1.11
per impaired item; 95% CI, 1.05–1.17), recent weight loss
(HR, 1.61; 95% CI, 1.14–2.28), and lower systolic blood
pressure (HR, 0.86 per standard deviation increase; 95% CI,
0.74–0.99). Creatinine clearance≤30 mL/min showed a trend
toward an association with 2-year mortality (HR, 1.36; 95%
CI, 0.97–2.00) [18].
3. Conclusions
Acute heart failure is a life-threatening medical condition,
which needs emergency management for death prevention.
4. Prospects for further research
Prospects of further researches are the discovering of new
kinds of medications for acute heart failure treatment.
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